Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression

prnasiaApril 02, 2021

Tag: Everest , Trodelvy , NMPA , sacituzumab govitecan-hziy

PharmaSources Customer Service